Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25262522 | 0.81 | F10 (0.33) | F10PTGS2 | |
| SCHEMBL198132 | 0.81 | PTGS2 (0.57) | F10PTGS2 | |
| SCHEMBL1418830 | 0.80 | F10 (0.43) | F10PTGS2 | |
| SCHEMBL76558 | 0.80 | F10 (0.58) | F10PTGS2 | |
| SCHEMBL2344200 | 0.79 | PTGS2 (0.44) | F10PTGS2 | |
| SCHEMBL19456 | 0.79 | PTGS2 (0.64) | F10PTGS2 | |
| SCHEMBL18630668 | 0.79 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL15846877 | 0.79 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL2540317 | 0.79 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL92872 | 0.79 | PTGS2 (0.64) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| EP-3201208-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-03-24 | — | — | EP | claimed |
| EP-3201207-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | claimed |
| EP-3201205-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | claimed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | claimed |
| US-20180105539-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-19 | — | — | US | claimed |
| US-20180105538-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-19 | — | — | US | claimed |
| CN-107250116-A | 3,5 diamino-pyrazole kinase inhibitors | 埃克希金医药品有限公司 | 2017-10-13 | — | — | CN | claimed |
| EP-3201208-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | claimed |
| EP-3201207-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | claimed |
| EP-3201205-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | claimed |
| WO-2016050359-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | claimed |
| WO-2016050356-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | claimed |
| WO-2016050355-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | disclosed |
| EP-1583761-A1 | METHOD FOR PRODUCING 5-CHLORO- i N /i -({5 i S /i )-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&rc ub;-METHYL)-2-THIOPHENE CARBOXAMIDE | Bayer HealthCare AG (DE) | 2005-10-12 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105539-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | F10 4009/4885PTGS2 4104/4885 |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | F10 4009/4885PTGS2 4104/4885 |
| US-20180105538-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | F10 4009/4885PTGS2 4104/4885 |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | F10 4109/4885PTGS2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.